Navigation Links
Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
Date:12/4/2007

CLEVELAND, Dec. 4 /PRNewswire/ -- An independent panel of scientists has awarded Ganeden Biotech, Inc. self-affirmed GRAS (Generally Recognized as Safe) status for its patented probiotic, GanedenBC30 (Bacillus coagulans GBI- 30, 6086). After an extensive evaluation of research studies and toxicology data, the panel concluded that GanedenBC30 is safe for use as an ingredient in food products. According to the FDA, self-affirmed GRAS status is awarded to any substance that is generally recognized among qualified experts as having been adequately shown to be safe under the conditions of its intended use.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041213/CLM031LOGO )

"With so many health benefits and potential applications available for GanedenBC30, licensing partners now have one more level of confidence in the safety of GanedenBC30 as an ingredient," commented Ganeden's Founder and Chief Scientist, Sean Farmer. "Achieving GRAS status further supports our commitment to provide superior probiotic bacteria in widely available premium products," Farmer said.

GanedenBC30 (Bacillus coagulans GBI-30, 6086) is a high-survivability strain of the probiotic, Bacillus coagulans. In addition to food products, GanedenBC30 is currently used in a broad range of applications including dietary supplements, animal health products, feminine hygiene and topical applications. The probiotic cells in GanedenBC30 are able to survive very harsh manufacturing processes, do not require refrigeration and survive gastric acidity. Overall, GanedenBC30 has shown to be heartier than other probiotic strains and exhibits excellent stability, offering more flexibility in manufacturing and delivery systems.

"GanedenBC30 is different from other traditional bacteria because it is surrounded by a natural organic layer that serves as a protective shield against the manufacturing process, shelf life and stomach acids and intestinal bile," explains Farmer. "Because of this unique make-up, GanedenBC30 survives the hostile environment of the stomach, colonizes the intestines, and produces lactic acid, which are all critical factors to the success of a probiotic. That's why we initially chose a strain of Bacillus coagulans over other conventional probiotic strains," explained Farmer.

About Ganeden Labs

Established in 2006, Ganeden Labs is the licensing and development division of Ganeden Biotech, making proprietary, patented probiotic technology available for use in innovative products in a wide range of industries. Ganeden maintains an extensive intellectual property portfolio with patent and trademark protection for an array of technologies all over the world. GanedenBC30 and its related patents are available for license in a wide variety of applications. For more information, visit http://www.ganedenlabs.com.

About Ganeden Biotech

Founded in 1997, Ganeden Biotech Inc. is a consumer healthcare company based in Cleveland, Ohio that features a popular line of over-the-counter, products under the brand names Sustenex, Digestive Advantage, and Clearly Confident. Ganeden's oral products including Sustenex and Digestive Advantage contain GanedenBC30, a patented strain of Bacillus coagulans.


'/>"/>
SOURCE Ganeden Biotech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):